Stiris Research Inc. announces completion of Site Closeout Visits in their Phase II Hormone Refractory Castrate-Resistant Prostate Cancer (HRCPC) study

London, ON — May 24, 2018 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the completion of all 10 Closeout Visits (COVs) of North American Investigative Sites who participated in the extension phase of a Phase II Hormone-Refractory Castrate-Resistant Prostate Cancer (HRCPC) study.

“The achievement of this important milestone will allow our Sponsor partner to focus on the review and analysis of safety and long-term follow up data for HRCPC subjects previously treated with their molecule.  We are pleased to have been able to contribute to ensuring subject safety and data integrity and to the knowledge base about the treatment of HRCPC,” said Kara Lee McWatters, Project Director at Stiris.

“The closure of this study completes an five year long relationship with this client and compound, and we are excited to see what lies ahead for them in their future development of novel treatments for men with prostate cancer,” said Amanda Carrera, Vice President at Stiris.

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.